BioSpace News Archive

Catawba Research announced a new partnership with Elligo Health Research, the largest healthcare-enabling research organization, that will expand access to clinical trials.

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure.

MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”) announced today that its Investigational New Drug (IND) application for a Phase 2 clinical trial of oral MYMD-1® as a treatment for rheumatoid arthritis (RA) was recently cleared by the U.S. Food and Drug Administration (FDA), and plans are underway for trial launch in the first quarter of 2024.

bit.bio, the company coding human cells for novel cures, has launched ioMotor Neurons as its 12th ioCells product this year.

Bering Limited, a London-based medical AI company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its AI-powered chest X-Ray

BriaCell Therapeutics Corp. is thrilled to announce continued outstanding topline survival and clinical benefit data in advanced metastatic breast cancer patients treated Bria-IMT™ in combination with an immune check point inhibitor (CPI).

Mosie Baby, a pioneering at-home fertility care company, has secured FDA Class II clearance for its Mosie Baby Kit making it the first and only FDA-cleared over-the-counter kit for use in intravaginal insemination (IVI).

SpineX Inc. is today announcing close to full recruitment -- over 80% -- of the patient cohort for its clinical trial of its proprietary SCONE™ device.

GENFIT (Nasdaq and Euronext: GNFT) today announced the publication in the Journal of Hepatology2 of a paper on the performance of NIS2+™ as a screening tool for the enrollment of patients in Metabolic Dysfunction–Associated Steatohepatitis (MASH) clinical trials.

Ten63 Therapeutics announced today a multi-target drug discovery collaboration with Boehringer Ingelheim.